Cancer Epidemiology Biomarkers & Prevention · 2011 · 143 citations · 34 references
MedicineOncologyPathologyCancer EpidemiologyCancer ScreeningCytopathologyCervical CancerCervical CytologyCervical Intraepithelial NeoplasiaCervical LesionsCervical PathologyCervicovaginal CytologyCervical Cancer Risk AssessmentCervical Cancer ScreeningCervical Intraepithelial Neoplasia 3Cervical Intraepithelial Neoplasia DiagnosisCohort Study InvestigationInvasive Cervical CarcinomaKaplan-meier Confidence IntervalsKaplan-meier Survival Estimates
BACKGROUND: Human papillomavirus (HPV) DNA testing is more sensitive than cytology for detection of cervical intraepithelial neoplasia grade 3 and cancer (≥CIN3). Adding HPV testing to cytology is recommended for women ≥30 but long-term prospective studies of HPV testing are rare. METHODS: Beginning in 1989-1990, ~20,000 women in a prepaid health maintenance organization (median age = 34) were followed passively by recommended annual cytology. We tested archived cervicovaginal lavage specimens collected at enrollment, primarily by MY09-MY11 PCR-based methods, for carcinogenic HPV types. We calculated positive and negative predictive values for the entire study period, and Kaplan-Meier estimates of cumulative probability for ≥CIN3, up to 18 years of follow-up. RESULTS: We observed 47 cases of invasive cervical cancer during the study period, and 156 cases of CIN3. Predictive values and Kaplan-Meier analyses yielded the same conclusions. In women 30 and older, the reassurance against ≥CIN3 following a single negative HPV test was long-lasting (cumulative probability = 0.7% during follow-up). In this age group, a single HPV test (positive vs. negative, hazard ratio of 8.5, 95% CI = 4.8-15.1) provided greater long-term risk stratification than a single cytologic result (abnormal vs. normal, HR = 2.9, 95% CI = 1.2-6.6). The risk for ≥CIN3 was higher for HPV16 than for the average of the other carcinogenic types (hazard ratio = 2.7). CONCLUSION AND IMPACT: The data from this cohort study show the long-term predictive value of HPV testing, particularly in women ≥30, and a possible role for distinguishing particularly carcinogenic types like HPV16.
34
Michelle J. Khan, Philip E. Castle, Attila T. Lörincz et al. · JNCI Journal of the National Cancer Institute · 2005 · 1.1K citations · Full text
Human Papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer
Pontus Nauclér, Walter Ryd, Sven Törnberg et al. · New England Journal of Medicine · 2007 · 807 citations
Medicine, Gynecology, Oncology +17